Cellebrite DI Ltd. (NASDAQ: CLBT) reported Q3 EPS of $0.05, versus $0.03 reported last year. Revenue for the quarter came in at $65.9 million, versus $53.24 million reported last year.

GUIDANCE:

Cellebrite DI Ltd. sees FY2021 revenue of $241.5-243.5 billion, versus the consensus of $234.4 billion.

• Full year 2021 Adjusted EBITDA is expected to be between $45.0 and $46.5 million, representing a 19% margin at the mid-point, up from prior guidance of $36.0 million and a 15% margin.

For earnings history and earnings-related data on Cellebrite DI Ltd. (CLBT) click here.